DEERFIELD, Ill., June 30, 2020 (GLOBE NEWSWIRE) — RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today provided a business update in conjunction with releasing financial and operating results for the quarter ended March 31, 2020.
Business Update Highlights:
- Scheduled special meeting of stockholders for July 15, 2020 to vote on sale of OEM business
- Announced two senior leadership appointments and a new director to support transition to a pure-play global spine company
- First quarter 2020:
- Revenue of $73.7 million, up 5% compared to the first quarter of 2019
- Net loss of $17.9 million, or $0.24 per common share
- Adjusted EBITDA of $1.4 million, or 2% of revenue
“I am very proud of the actions taken by our entire organization over the last several months as we have navigated the COVID-19 pandemic while at the same time managing through the pending sale of the OEM business and a number of other headwinds,” said Camille Farhat, President and CEO, RTI Surgical. “The integrity, dedication, and talent of our people have enabled us to come out on the other side of this unique period in time ready to take advantage of the opportunities that exist in the Spine market for high-value surgical solutions.”
Farhat continued, “We view the recent disruption as transitory, and despite the uncertainty associated with COVID-19, we remain very confident in the long-term prospects of the Spine business. We are targeting double-digit long-term revenue growth with gross margins of 75% by executing on our strategy of build, innovate, and acquire. We are very excited about this next phase of RTI’s transformation.”
Annual Meeting and Special Meeting of Stockholders
The company will hold its annual meeting of stockholders on July 15, 2020. Among the matters to be considered and voted on at the Annual Meeting, which, as previously disclosed, will be combined with a special meeting of the stockholders, are the various proposals necessary to approve the transactions contemplated by the previously announced Equity Purchase Agreement, dated January 13, 2020, as amended, with Ardi Bidco Ltd., a Delaware corporation and an entity affiliated with Montagu Private Equity, LLP (the “Buyer”), pursuant to which the Buyer will acquire the OEM business of the Company by means of a sale of certain affiliates of the Company.
Spine Business Update
On June 10, 2020 The Company announced two senior leadership appointments to support its transition to a pure-play global spine company. Scott Durall joined RTI as Chief Commercial Officer, and Bryan Cornwall joined RTI as Executive Vice President, Research and Clinical Affairs, both effective June 15, 2020. Durall and Cornwall bring to RTI decades of commercial, operational and scientific expertise, and will support the Company’s ongoing focus on becoming a leader in the global spine market following the close of the pending sale of the OEM business. Please see our related press release for more detail on their backgrounds.
In addition, on June 1, Stuart F. Simpson joined the Board of Directors and was recently named Vice Chairman of the Board. Mr. Simpson brings decades of industry experience which will be valuable in supporting RTI’s strategy as a pure-play global spine company.
First Quarter 2020 Financial Results
RTI’s worldwide revenues for the first quarter of 2020 were $73.7 million, an increase of $3.7 million, or 5% compared with $70.0 million during the same period in the prior year. Gross profit for the first quarter of 2020 was $40.5 million, or 55% of revenues, a 7.0% increase compared to $37.9 million, or 54% of revenues, in the first quarter of 2019.
Net loss applicable to common shares was $17.9 million, or $0.24 per fully diluted common share in the first quarter of 2020, compared to net loss applicable to common shares of $9.4 million, or $0.14 per fully diluted common share in the first quarter of 2019.
Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA), for the first quarter of 2020 was $1.4 million, or 2% of revenues, compared with $7.0 million, or 10% of revenues for the first quarter of 2019. The decrease in Adjusted EBITDA was primarily driven by annualization of costs related to the Paradigm acquisition and incremental investment for the separation of the business to support the sale of the OEM business.
2020 Outlook
Due to the inability to estimate the size and impact of the COVID-19 pandemic on the Company’s operations and financial results, RTI Surgical Holdings, Inc. will not provide guidance for fiscal year 2020. We will continue to evaluate the COVID-19 pandemic on our operations and financial results and will provide additional information when we are more certain.
Conference Call
RTI will host a conference call and audio webcast at 9:00 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International), using conference ID 6346397. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com/investors. A replay of the conference call will be available on RTI’s website for one month following the call.
